Arcus Biosciences - Investors & Media - Press Releases
Oct 24, 2024 · Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pi... Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall... Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimbereli... First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed ...
Arcus Biosciences, Inc. (RCUS) Latest Stock News & Headlines
Get the latest Arcus Biosciences, Inc. (RCUS) stock news and headlines to help you in your trading and investing decisions.
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 · With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer.
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History ...
Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Arcus Biosciences | Pursuit of Cures for Cancer
Arcus is at the forefront of designing combination therapies, with best-in-class potential, in our relentless pursuit of cures for cancer. Featured Arcus News: Arcus Announces Overall Survival Data for Domvanalimab Plus Zimberelimab in ARC-10, a Randomized Study in Patients with PDL-1-High Non-Small Cell Lung Cancer
Arcus Biosciences to Present New Data for Anti-TIGIT …
HAYWARD, Calif., October 30, 2024 -- (BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...
Arcus, Iteos Soar On Roche's 'Meaningful' Results In A New …
May 26, 2023 · Shares of Arcus Biosciences and Iteos Therapeutics surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class. RCUS stock easily retook its 50-day line.
Arcus Biosciences: Neutral Rating Amid Early-Stage Data …
Oct 25, 2024 · The confidence displayed by Arcus Biosciences regarding their drug casdatifan suggests optimism, particularly in its potential to improve upon existing treatments like Merck’s Welireg.
Optimistic Buy Rating for Arcus Biosciences Amid Promising …
Jan 24, 2024 · Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) on January 22 and set a price target of $51.00. Mara Goldstein has given her Buy...
Arcus Biosciences (RCUS) News Today - MarketBeat
Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 118,693 shares of the company's stock after acquiring an additiona.